Effects of beraprost sodium on plasma VEGF and ET-1 in elderly patients with type 2 diabetic nephropathy
10.3760/cma.j.issn.1674-6090.2013.06.006
- VernacularTitle:贝前列素钠对老年2型糖尿病肾病患者血浆血管内皮生长因子及内皮素-1的影响
- Author:
Juan HUANG
;
Yunfang HUANG
;
Wenli CHEN
- Publication Type:Journal Article
- Keywords:
Beraprost sodium;
Diabetic nephropathy;
Vascular endothelial growth factor;
Endothelin;
UAER
- From:
Journal of Endocrine Surgery
2013;7(6):463-465
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect of beraprost sodium on elderly patients with type 2 diabetic nephropathy (DN) and to observe the change of the plasma vascular endothelial growth factor(VEGF) and endothelin(ET-1) level.Methods The levels of plasma VEGF and ET-1 in the 27 cases of type 2 diabetes without nephropathy and 48 cases with type 2 diabetic nephropathy were measured.The possible role of VEGF and ET-1 in diabetic nephropathy was explored.48 cases of type 2 diabetic nephropathy patients were randomly divided into 2 groups:the conventional treatment group and beraprost sodium treatment group.The changes of VEGF and ET-1 level in the 2 groups before and after the treatment were measured.Results The plasma VEGF and ET-1 levels were significantly higher in type 2 diabetic nephropathy patients than in type 2 diabetes patients without nephropathy(P ＜0.01).Compared with the control group,beraprost sodium significantly reduced the plasma VEGF and ET-1 levels in patients with diabetic nephropathy(P ＜ 0.05),and also reduced urinary albumin excretion rates (UAER) significantly (P ＜ 0.05).Conclusions The increasing level of VEGF and ET-1 plays an important role in the onset of diabetic nephropathy.Beraprost sodium can correct the balance of the plasma VEGF and ET-1 in treatment of patients with diabetic nephropathy,improves the endothelial function in diabetic nephropathy,decreases urine protein,and plays a protective role in diabetic nephropathy.
